The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping

Pharmacogenetics and Genomics

Volumn 24, Issue 8, 2014, Pages 381-386

  Langaee, Taimour Y ^a   Zhu, Hao Jie ^a,b   Wang, Xinwen ^a,b,c   El Rouby, Nihal ^a   Markowitz, John S ^a   Goldstein, Joyce A ^d   Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

clopidogrel; CYP2C19*10; genotyping; pharmacogenetic; pharmacokinetic

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; DNA; MEPHENYTOIN; OMEPRAZOLE; 2 OXO CLOPIDOGREL; 2-OXO-CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG HYDROXYLATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; CATALYSIS; DNA SEQUENCE; GENETICS; KINETICS; LIQUID CHROMATOGRAPHY; METABOLISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CHROMATOGRAPHY, LIQUID; GENOTYPE; HUMANS; KINETICS; MEPHENYTOIN; OMEPRAZOLE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TANDEM MASS SPECTROMETRY; TICLOPIDINE;

EID: 84904154927     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000068     Document Type: Article

References (16)

1. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002; 12:703-711.
2. Wang H, Kim RA, Sun D, Gao Y, Wang H, Zhu J, Chen C. Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica 2011; 41:826-835.
3. Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol 2012; 166:2362-2370.
4. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328-332.
5. Rasmussen H, Werge T. Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure. Genet Test 2008; 12:57-58.
6. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8:129-135.
7. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 2013; 344:665-672.
8. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. Highthroughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19:2651-2658.
9. Zhang W, Han F, Guo P, Zhao H, Lin ZJ, Huang MQ, et al. Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS-a high throughput approach to evaluate drug-drug interactions. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1169-1177.
10. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157:442-449.
11. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P. Rationale and design of the international verapamil SR/trandolapril study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32:1228-1237.
12. Langaee TY, Ronaghi M. Genetic variation analyses by pyrosequencing. Mutat Res 2005; 573 (1-2):96-102.
13. Tsao CC, Wester MR, Ghanayem B, Coulter SJ, Chanas B, Johnson EF, Goldstein JA. Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9. Biochemistry 2001; 40:1937-1944.
14. Wada Y, Mitsuda M, Ishihara Y, Watanabe M, Iwasaki M, Asahi S. Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. J Biochem 2008; 144:323-333.
15. Lee SJ, Kim WY, Kim H, Shon JH, Lee SS, Shin JG. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos 2009; 37:2262-2269.
16. Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 2009; 39:836-843.